Back to results
US 12,325,880 B2Granted
Identification of PDE3 modulator responsive cancers
AssigneeThe Broad Institute, Inc.
InventorsXiaoyun Wu, Heidi Greulich
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThe Broad Institute, Inc.
InventorsXiaoyun Wu, Heidi Greulich
Estimating the term…
The present disclosure features methods for identifying pateints having a hyperproliferative disease, disorder, or condition responsive to phosphodiesterase 3 (PDE3) and schlafen family member 12 (SLFN12) complex formation. The hyperproliferative disease, disorder, or condition may be cancer in a patient including glioblastoma, melanoma, ovarian cancer, cervical cancer, sarcoma, or hematopoietic cancers, such as acute myeloid leukemia. Those responsive diseases, disorders, or conditions may be identified using the biomarker AIP and/or TRRAP in combination with those biomarkers pertinent to phosphodieseterase 3 and schlafen family member 12 complexes which may be formed by PDE3 modulation with certain active compounds. Expression of combinations of these biomarkers have been shown to correlate with active compound (e.g., PDE3 modulator, PDE3A modulator, PDE3B modulator) sensitivity.
A method of killing or reducing the survival of a cell selected as responsive to PDE3A-SLFN12 complex formation or PDE3B-SLFN12 complex formation comprising contacting said cell with a PDE3 modulator, wherein said cell is selected as responsive to said PDE3 modulator when said cell:
A method for the treatment of a hyperproliferative disease, disorder, or condition in a subject comprising administering to said subject a PDE3 modulator, wherein said subject is identified as having a hyperproliferative disease, disorder, or condition that is responsive to the PDE3 modulator by obtaining one or more cells of the hyperproliferative disease, disorder, or condition from the subject and detecting:
Dependencies are inferred from the claim text.